Neuroleptic Malignant Syndrome in a Young Male on Clozapine: A Diagnostic and Therapeutic Challenge

Neuroleptic malignant syndrome (NMS) is a rare but potentially life-threatening adverse reaction associated with antipsychotic medications. It is characterized by hyperthermia, severe muscle rigidity, altered mental status, autonomic instability, and elevated creatine kinase (CK) levels. Although commonly linked with first-generation antipsychotics, it may also occur with atypical agents such as clozapine.

We report the case of a 34-year-old male with a history of psychiatric illness receiving long-term clozapine therapy who presented with altered sensorium and generalized rigidity. During hospitalization, he developed hyperthermia and markedly elevated CK levels. After exclusion of infectious, metabolic, and structural causes, a diagnosis of NMS was considered. The patient was managed with discontinuation of antipsychotic medication, intensive supportive care, and treatment with bromocriptine. However, despite aggressive management, his clinical condition progressively deteriorated and resulted in death.

This case highlights the importance of early recognition of NMS in patients receiving antipsychotic therapy. Prompt diagnosis, withdrawal of the offending drug, and aggressive supportive treatment are essential to improve outcomes and reduce mortality.